Does Humana Cover Cialis (Tadalafil)? Coverage, Prior Auth and Appeals Explained

What Is Tadalafil and Why Does Coverage Classification Matter?

Tadalafil is a phosphodiesterase type-5 (PDE5) inhibitor approved by the FDA in 2003 for erectile dysfunction and in 2011 for benign prostatic hyperplasia (BPH) under the brand name Cialis. It is also approved at 2.5 to 5 mg daily for pulmonary arterial hypertension (PAH) under the brand name Adcirca. The indication printed on your prescription determines which benefit category Humana applies, and that classification can be the difference between a $20 copay and a full out-of-pocket cost.

Brock et al. (J Urol 2002, N=179) demonstrated that tadalafil produced statistically significant improvements in International Index of Erectile Function (IIEF) scores compared with placebo at doses of 10 mg and 20 mg, establishing the foundational efficacy data the FDA relied on for approval 1. The FDA label confirms approval for three distinct indications: ED, BPH, and PAH 2. Those three indications map to entirely different formulary buckets at most insurers, including Humana.

Generic tadalafil entered the U.S. market in September 2018 after Lilly's patent exclusivity expired. Since then, the generic has displaced the brand on commercial formularies at a rate that mirrors other post-patent PDE5 inhibitors. The American Urological Association (AUA) 2018 guideline on ED lists PDE5 inhibitors as first-line therapy 3, creating a guideline basis your physician can cite in a prior-authorization letter.

How Humana Classifies Tadalafil on Its Formulary

Humana's formulary tier for tadalafil depends on whether you have a commercial (employer-sponsored or individual marketplace) plan or a Medicare Advantage plan, and on the specific plan year.

On most Humana commercial plans, generic tadalafil sits at Tier 2 (preferred generic), carrying a typical copay of $10, $40 per 30-day supply after the deductible. Brand-name Cialis, when listed at all, appears at Tier 3 or Tier 4 (non-preferred brand), with cost-sharing of $50, $110 per fill or 30 to 50% coinsurance 4. Some commercial plans place brand Cialis on the excluded list entirely, meaning no benefit applies regardless of medical necessity.

On Humana Medicare Advantage (MA) plans, CMS regulations at 42 CFR §423.120(b)(1) explicitly prohibit Part D coverage of drugs used for sexual dysfunction 5. Because the primary FDA indication for Cialis is ED, Humana MA plans default to non-coverage. However, tadalafil prescribed specifically for BPH (ICD-10 code N40.x) occupies a different regulatory space and is not categorically excluded. Several Humana MA plans include tadalafil 5 mg on the formulary when the submitted diagnosis code is BPH. The specific Humana plan Evidence of Coverage (EOC) document for the plan year governs; always verify through the Humana online drug lookup tool before assuming exclusion or inclusion.

A 2021 analysis published in JAMA Network Open found that PDE5 inhibitor out-of-pocket costs under Medicare Part D averaged $123 per fill for beneficiaries who paid any cost-sharing, underscoring how formulary tier materially affects access for older patients 6.

Prior Authorization Criteria for Tadalafil on Humana Plans

Prior authorization (PA) is required on the majority of Humana plans for tadalafil, particularly for Medicare Advantage and for higher-dose commercial prescriptions (10 mg or 20 mg as-needed formulations). The PA criteria Humana typically applies include:

1. A confirmed diagnosis of ED or BPH documented in the clinical notes.
2. Prescriber attestation that the patient has no contraindications (concurrent nitrate use is an absolute contraindication identified in the tadalafil prescribing information) 7.
3. Step therapy completion (see the next section).
4. Quantity limits: most Humana PA approvals cap dispensing at 6 tablets per 30 days for as-needed dosing or a 30-day supply of the 2.5 mg or 5 mg daily formulation.

For BPH, Humana's clinical criteria generally align with the AUA BPH guideline, which endorses tadalafil 5 mg daily as an option for men with BPH and co-existing ED 8. Including both the BPH diagnosis code and the ED diagnosis code on the PA request, when both apply clinically, may broaden the qualifying criteria the reviewer considers.

Humana's PA submissions are processed through CoverMyMeds or directly through the Humana Provider Portal. Commercial PA decisions arrive within 72 hours for standard requests; Medicare Advantage urgent requests receive a 24-hour turnaround by federal regulation 9.

The prescribing physician's documentation should explicitly state the clinical rationale, the duration of symptoms, and the absence of contraindications. A note that reads "patient has ED" is far weaker than a note citing an IIEF-5 score below 21, duration of 12 months, and failure of lifestyle modification.

Step Therapy Requirements: What Humana Expects Before Approving Tadalafil

Step therapy means a plan requires trial of a lower-cost alternative before approving the requested drug. On most Humana commercial plans, sildenafil (generic Viagra) is the required first-step agent for ED. Sildenafil has been generic since 2017 and costs under $1 per tablet at many pharmacies, making it the dominant first-line formulary choice for PDE5 inhibitor PA programs 10.

A standard Humana step therapy sequence for tadalafil on commercial plans looks like this:

• Step 1: Trial of generic sildenafil 50 mg or 100 mg for at least 4 to 6 weeks with an adequate number of attempts (typically six or more attempts documented).
• Step 2: Documentation of inadequate response, intolerance, or a clinical reason the patient cannot use sildenafil (for example, timing inflexibility or visual disturbances).
• Step 3: PA approval of tadalafil at the lowest effective dose.

Several states have enacted step therapy override laws requiring insurers to grant exceptions within specific timelines when a prescriber documents a clinical reason. As of 2024, 37 states plus the District of Columbia have such laws on the books 11. If your state has this protection and your Humana commercial plan is state-regulated (not an ERISA self-funded plan), your physician can submit a step therapy exception request on day one.

Medicare Advantage plans are subject to the Medicare step therapy rule finalized in 2018, which requires plans to have an exception process and to respond to exception requests within 72 hours (24 hours for expedited requests) 12.

For BPH-indicated tadalafil, step therapy requirements are less standardized. Some Humana plans require trial of an alpha-blocker (tamsulosin 0.4 mg is the most common) before approving tadalafil for BPH. The AUA BPH guideline supports combination alpha-blocker plus tadalafil therapy for men who respond inadequately to monotherapy 8, so prior alpha-blocker use can actually strengthen a PA request rather than block it.

How to Appeal a Humana Denial of Tadalafil

Denials happen. The appeal process differs depending on whether you have commercial or Medicare Advantage coverage.

Commercial Plan Appeals

Humana commercial plan members have the right to an internal appeal, followed by an external review through an independent review organization (IRO) if the internal appeal fails. Federal ACA rules require insurers to issue internal appeal decisions within 30 days for pre-service appeals (15 days for urgent requests) 13. A compelling appeal letter for tadalafil should include:

• The prescribing physician's clinical notes documenting diagnosis, symptom duration, and IIEF-5 score.
• Documentation of the sildenafil step therapy trial, including dates, doses, and reason for failure.
• A reference to the AUA guideline supporting tadalafil as first-line or appropriate second-line therapy 3.
• Any relevant comorbidities (diabetes, post-prostatectomy status, cardiovascular disease) that explain the clinical preference for tadalafil's longer half-life (17.5 hours) compared to sildenafil (4 hours) 14.

The longer half-life point carries clinical weight. A 2004 crossover study in the European Urology journal (N=150) found that 73% of men preferred tadalafil over sildenafil after trialing both, citing the extended window of responsiveness as the primary reason 15. Citing a patient preference study is not sufficient on its own, but it supports the clinical narrative in an appeal.

Medicare Advantage Appeals (MAXIMUS Process)

For Humana MA denials, the five-level CMS appeal chain applies:

1. Level 1: Humana internal redetermination (within 7 days standard, 72 hours expedited).
2. Level 2: Qualified Independent Contractor (QIC) review through MAXIMUS Federal Services (within 7 days standard, 72 hours expedited) 16.
3. Level 3: Office of Medicare Hearings and Appeals (OMHA) Administrative Law Judge hearing.
4. Level 4: Medicare Appeals Council review.
5. Level 5: Federal district court (if the amount in controversy exceeds $1 to 840 in 2025).

For MA appeals specifically challenging the ED exclusion, the strongest argument is a dual diagnosis: the prescriber must document that tadalafil is being prescribed for BPH (or PAH), not for ED. CMS has confirmed in sub-regulatory guidance that drugs excluded for one indication are not automatically excluded when prescribed for a separate covered indication 17.

A 2020 OIG report found that Part D plan denials were overturned at the MAXIMUS level at a rate of approximately 75% when beneficiaries submitted medical records supporting the request 18. File the appeal. Most denials go unchallenged.

Cost Alternatives When Humana Does Not Cover Tadalafil

Coverage denial does not mean tadalafil is unaffordable. Generic tadalafil is one of the most price-competitive prescription drugs in the U.S. market.

Cash-pay pricing: GoodRx and similar discount platforms list generic tadalafil 5 mg (30 tablets) for $20, $35 at major pharmacy chains as of mid-2025. The 20 mg tablet (30 count) runs $30, $60 depending on pharmacy 19. Using a cash-pay coupon at a pharmacy is often cheaper than paying the Humana Tier 3 cost-sharing even when coverage exists.

Manufacturer savings card: Eli Lilly offers a Cialis savings program for commercially insured patients. Federal law prohibits using manufacturer coupons when the patient is covered by any federal program, including Medicare, Medicaid, or TRICARE 20. Humana commercial plan members are generally eligible for Lilly savings cards; Humana MA members are not.

Telehealth prescribers: Several telehealth platforms prescribe generic tadalafil through a $30, $60 monthly subscription model. These programs are cash-pay by design and sidestep the Humana formulary entirely. If Humana refuses coverage and the monthly cash cost is under your plan's deductible anyway, the telehealth route is a practical option for many patients.

90-day supply: When Humana does cover generic tadalafil, ordering a 90-day supply through Humana's mail-order pharmacy (Humana Pharmacy) typically reduces per-unit cost by 15 to 25% compared to 30-day retail fills.

A 2019 survey published in Urology (N=2,102) found that 43% of men with ED who abandoned PDE5 inhibitor prescriptions cited cost as the primary barrier, while only 18% cited side effects 21. Addressing the cost pathway directly with patients reduces that abandonment.

Tadalafil for BPH: A Separate Coverage Path on Humana

The BPH indication is the most underused route for securing Humana coverage of tadalafil, particularly on Medicare Advantage plans. BPH affects approximately 50% of men aged 51, 60 and 90% of men over 80, per the National Institute of Diabetes and Digestive and Kidney Diseases 22. Many men with ED also have BPH, and the FDA has approved tadalafil 5 mg daily for both conditions simultaneously 2.

A key multicenter trial (N=325) published in the Journal of Urology demonstrated that tadalafil 5 mg daily reduced International Prostate Symptom Score (IPSS) by 3.8 points from baseline versus 1.7 points for placebo (P<0.001) at 12 weeks 23. That placebo-controlled evidence base gives the BPH indication strong clinical standing.

When a Humana MA plan denies tadalafil for ED but the patient also has documented BPH, the prescriber should resubmit the PA request with the BPH ICD-10 code (N40.1 for BPH with lower urinary tract symptoms) as the primary diagnosis. This is not a workaround; it is accurate coding when both conditions are clinically present and tadalafil is indicated for both.

Does Humana Cover Tadalafil for Pulmonary Arterial Hypertension?

Tadalafil 20 mg (Adcirca) for PAH is a separate formulary consideration and is almost universally covered by both Humana commercial and Humana MA plans because PAH has no CMS exclusion and carries a serious-condition designation. The list price for Adcirca runs approximately $2,100 per month, and specialty tier PA is standard. The FDA approved tadalafil for PAH in 2009 based on the PHIRST trial (N=405), which showed a 33-meter improvement in 6-minute walk distance at 16 weeks versus placebo 24. That indication is outside the scope of the ED/BPH formulary discussion above but worth noting for clinicians managing patients with PAH on Humana plans.

What Humana's Medical Policy Says About Tadalafil: Key Language

Humana publishes medical coverage policies online. The relevant policy for tadalafil is categorized under "Drugs for Erectile Dysfunction" and "Drugs for Benign Prostatic Hyperplasia." The ED policy states, in relevant part, that coverage for ED medications is subject to plan benefit limitations and that Medicare Advantage plans follow CMS regulations excluding coverage for sexual dysfunction drugs absent a separate covered indication.

The AUA Clinical Practice Guideline on ED (2018, reaffirmed 2022) states: "Phosphodiesterase type 5 inhibitors are recommended as first-line therapy for the majority of men with erectile dysfunction" 3. That language, cited directly in a PA or appeal letter, positions tadalafil not as a lifestyle drug but as guideline-endorsed first-line therapy.

Humana's BPH drug policy cross-references the AUA BPH guideline (2022 update), which lists tadalafil 5 mg daily as an appropriate pharmacologic treatment for men with LUTS attributed to BPH, regardless of whether ED is co-present 8.

Practical Checklist: Maximizing Your Chance of Humana Approval

Getting tadalafil approved on a Humana plan is achievable with the right documentation. Here is what the prescriber's office should send with every PA request:

• Office notes with ICD-10 codes for ED (N52.9) and/or BPH (N40.1), including symptom duration and validated questionnaire scores (IIEF-5 for ED, IPSS for BPH).
• Documentation of sildenafil trial, if applicable, including dose, duration, number of attempts, and reason for switch request.
• Absence of contraindications: nitrate medications (isosorbide, nitroglycerin), alpha-blockers at high dose (noting that the FDA label permits low-dose alpha-blocker co-administration with tadalafil 5 mg for BPH) 7.
• Comorbidity documentation: diabetes (ICD-10 E11.x), post-prostatectomy status (Z90.79), or cardiovascular disease, each of which may support a tadalafil-specific clinical rationale based on published pharmacokinetic and outcomes data 25.
• Reference to AUA ED or BPH guideline recommendation supporting tadalafil 3.

Submit via the Humana Provider Portal with a fax backup. Keep a timestamped confirmation. If no decision arrives within the federal timeline, that is grounds for a deemed denial and immediate appeal.